Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Urofollitropin and ovulation induction.

Madelon van Wely1, Claus Yding Andersen, Neriman Bayram

  • 1Department of Obstetrics and Gynaecology (H4-205), Center for Reproductive Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. m.vanwely@amc.uva.nl

Treatments in Endocrinology
|May 19, 2005
PubMed
Summary

Follicle-stimulating hormone (FSH) effectively induces ovulation in women with anovulation, particularly WHO type II. Urofollitropin and recombinant FSH show similar efficacy, with urinary-derived FSH offering a cost-effective alternative.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Follicular development during the follicular phase of the menstrual cycle: the enigma of luteinizing hormone receptor function.

Frontiers in endocrinology·2026
Same author

Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissues: impact and legacy two decades latter.

Human reproduction (Oxford, England)·2026
Same author

Letrozole administration during ovarian stimulation: intrafollicular concentrations, effects on steroidogenesis and pregnancy outcome-a secondary analysis.

Journal of assisted reproduction and genetics·2026
Same author

The ovulation trigger method affects gonadotropin concentrations and gonadotropin receptor expression during final oocyte maturation in women.

Frontiers in endocrinology·2026
Same author

From Preservation to Creation: The Expanding Frontier of Fertility Preservation - Proceedings of the 2<sup>nd</sup> Montreux Reproductive Summit, 29-30 August 2025.

Facts, views & vision in ObGyn·2026
Same author

Integrating impact of FSH isoforms, androgens and inhibin-B on follicular development based on a two-phase model of the follicular phase.

Reproductive biology and endocrinology : RB&E·2025

Area of Science:

  • Reproductive Endocrinology
  • Infertility Treatment
  • Hormone Therapy

Background:

  • Anovulation is a primary cause of female infertility, necessitating ovulation induction therapies.
  • Follicle-stimulating hormone (FSH) is a key treatment for WHO type II anovulation, especially in polycystic ovary syndrome (PCOS) patients unresponsive to clomiphene citrate.
  • Risks associated with FSH therapy include ovarian hyperstimulation syndrome (OHSS) and higher-order multiple pregnancies, emphasizing the need for careful administration protocols.

Purpose of the Study:

  • To compare the effectiveness and safety of urofollitropin (urinary-derived FSH) against other available gonadotropins for ovulation induction.
  • To evaluate the suitability of different FSH preparations in managing anovulatory infertility.

Main Methods:

  • Comparative analysis of urofollitropin (urinary FSH) with recombinant FSH and human menopausal gonadotropin (hMG).

Related Experiment Videos

  • Assessment of efficacy in terms of ovulation induction and pregnancy outcomes.
  • Evaluation of safety profiles, including risks of OHSS and multiple pregnancies.

    • Main Results:

    • Urofollitropin and recombinant FSH demonstrate comparable effectiveness and tolerability for ovulation induction.
    • Human menopausal gonadotropin shows similar pregnancy outcomes to urofollitropin.
    • The comparative risk of OHSS between hMG and urofollitropin in PCOS patients remains uncertain.

    Conclusions:

    • Urofollitropin and recombinant FSH are equally effective for ovulation induction, with recombinant options offering convenience but at a higher cost.
    • Urofollitropin remains a viable and cost-effective option for ovulation induction when cost is a significant factor.
    • Optimized FSH administration protocols, such as low-dose, gradual increment protocols, are crucial for minimizing complications.